VRTX on XNAS, Health Care, Vertex Pharmaceuticals Inc, job postings
Measures activity, not value. Not investment advice.
Revenue rose 10% to $13B and shares gained 22% in the past year.
GoodInstitutional holders rose to 1,772 from 1,717 last quarter
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.4B, net income $653.6M.
31 Dec 2021RevenueNet incomeNet losstallest bar $3.6B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$3.4B
$653.6M
30 Jun 2026
$3.3B
$1.1B
31 Mar 2026
$3.0B
$1.0B
31 Dec 2025
$3.2B
$1.2B
30 Sep 2025
$3.1B
$1.1B
30 Jun 2025
$3.0B
$1.0B
31 Mar 2025
$2.8B
$646.3M
31 Dec 2024
$2.9B
$913.0M
30 Sep 2024
$2.8B
$1.0B
30 Jun 2024
$2.6B
-$3.6B
31 Mar 2024
$2.7B
$1.1B
31 Dec 2023
$2.5B
$968.8M
30 Sep 2023
$2.5B
$1.0B
30 Jun 2023
$2.5B
$915.7M
31 Mar 2023
$2.4B
$699.8M
31 Dec 2022
$2.3B
$818.9M
30 Sep 2022
$2.3B
$930.5M
30 Jun 2022
$2.2B
$810.5M
31 Mar 2022
$2.1B
$762.1M
31 Dec 2021
$2.1B
$770.1M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$13.0B
$11.7B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+10%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$4.0B
$3.7B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$15.53
$14.21
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
85.5%
86.3%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
33.2%
34.1%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
30.7%
31.3%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
20.8%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$3.2B
$3.3B
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$6.3B
$6.3B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$4.5B
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$1.8B (net cash)
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.22
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$82.46
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
32.8
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
10.1
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
9.9
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
6.2
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$15.4M
bought $0, sold $15.4M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+3.2%
1,772 13F filers vs 1,717
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
94%
238.4M shares held by 13F filers (30 Sep 2026) of 253.5M outstanding (31 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
1.9%
4.8M shares sold short (30 Oct 2026) of 253.5M outstanding (31 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.4
4.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+13%
4.3M shares sold short in the report before, 4.8M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
48%
48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 51%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
268
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
+5.9%
198 vs 187 applications
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+12%
$3.4B vs $3.1B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-4.4%
$97.3M vs $101.8M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$4.6M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
48
48 articles in the last 7 days; its usual week has 6.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
7.4×
48 articles in the last 7 days; its usual week has 6.5.
Price $515.02 on 20 Nov 2026, +22% over 12 months (12-month range $422.32 to $558.88)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $140.1M in the last 12 months (the 12 months before: -$47.1M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 197 published in the last 12 months, +4.8% on the 12 months before.Revenue per quarter. Revenue $3.4B in the latest quarter, +12% on a year earlier.Capital spending per quarter. Capital spending $97.3M in the latest quarter, -4.4% on a year earlier.Institutional holders (13F filers). 1,772 13F filers reported holding it in the latest 13F quarter, +23% on a year earlier.Lobbying spend. Lobbying spend: $4.6M published in the last 12 months, -4.4% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $2.1B, +27% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $2.1B, +22% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $2.2B, +22% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $2.3B, +18% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $2.3B, +11% on a year earlier; public on 11 Feb 2023
Quarter ended 31 Mar 2023: $2.4B, +13% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $2.5B, +14% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $2.5B, +6.4% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $2.5B, +9.3% on a year earlier; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $2.7B, +13% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $2.6B, +6.1% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $2.8B, +12% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $2.9B, +16% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $2.8B, +3.0% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $3.0B, +12% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $3.1B, +11% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $3.2B, +9.5% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $3.0B, +7.8% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $3.3B, +12% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $3.4B, +12% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $61.7M, +29% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $63.6M, -10% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $53.3M, +6.9% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $54.2M, +3.2% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $33.6M, -46% on a year earlier; public on 11 Feb 2023
Quarter ended 31 Mar 2023: $42.1M, -34% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $59.6M, +12% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $40.6M, -25% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $58.1M, +73% on a year earlier; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $68.4M, +62% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $69.0M, +16% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $67.7M, +67% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $92.6M, +59% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $40.7M, -40% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $145.7M, +111% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $101.8M, +50% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $149.4M, +61% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $133.4M, +228% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $112.2M, -23% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $97.3M, -4.4% on a year earlier; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 915; public on 14 Feb 2022
31 Mar 2022 report: 1,002; public on 16 May 2022
30 Jun 2022 report: 1,029; public on 15 Aug 2022
30 Sep 2022 report: 1,018; public on 14 Nov 2022
31 Dec 2022 report: 1,117; public on 14 Feb 2023
31 Mar 2023 report: 1,121; public on 15 May 2023
30 Jun 2023 report: 1,179; public on 14 Aug 2023
30 Sep 2023 report: 1,181; public on 14 Nov 2023
31 Dec 2023 report: 1,331; public on 14 Feb 2024
31 Mar 2024 report: 1,407; public on 15 May 2024
30 Jun 2024 report: 1,467; public on 14 Aug 2024
30 Sep 2024 report: 1,448; public on 14 Nov 2024
31 Dec 2024 report: 1,468; public on 14 Feb 2025
31 Mar 2025 report: 1,533; public on 15 May 2025
30 Jun 2025 report: 1,478; public on 14 Aug 2025
30 Sep 2025 report: 1,437; public on 14 Nov 2025
31 Dec 2025 report: 1,588; public on 17 Feb 2026
31 Mar 2026 report: 1,639; public on 15 May 2026
30 Jun 2026 report: 1,717; public on 14 Aug 2026
30 Sep 2026 report: 1,772; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $630K published
Quarter from 1 Apr 2022: $520K published
Quarter from 1 Jul 2022: $520K published
Quarter from 1 Oct 2022: $710K published
Quarter from 1 Jan 2023: $370K published
Quarter from 1 Apr 2023: $670K published
Quarter from 1 Jul 2023: $630K published
Quarter from 1 Oct 2023: $890K published
Quarter from 1 Jan 2024: $920K published
Quarter from 1 Apr 2024: $1.1M published
Quarter from 1 Jul 2024: $980K published
Quarter from 1 Oct 2024: $1.0M published
Quarter from 1 Jan 2025: $970K published
Quarter from 1 Apr 2025: $1.6M published
Quarter from 1 Jul 2025: $1.1M published
Quarter from 1 Oct 2025: $1.1M published
Quarter from 1 Jan 2026: $1.1M published
Quarter from 1 Apr 2026: $1.1M published
Quarter from 1 Jul 2026: $1.2M published
Quarter from 1 Oct 2026: $1.2M published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is H-1B/E-3 applications certified at 42 (Aug 2026), 4.0× its normal month; higher than 96% of its own history.
268 open postings; careers site tracked since 20 Nov 2026. Most in Research & science 9%, Test, quality & reliability 6%, Data & analytics 6%, Sales & business development 4%.
Reported lobbying spend: $1.2M in Q3 2026, $1.2M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Two or more unrelated kinds of records unusual within 30 days
17 Feb 2026confirmed
Confirmed across sources Filings + Financials and Lobbying
Vertex Pharmaceuticals(VRTX): lobbying on a new issue, while it spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 27 days.
Lobbying: Lobbying on a new issue, became public on 21 Jan 2026
Financials: Quarterly capital spending jump, became public on 17 Feb 2026
The quarter ended 31 Dec 2025 against the 8 quarters before it.
this quarterearliernormal: $68.7MSee the evidence (2 changes)
Lobbying: Lobbying on a new issue became public on 21 Jan 2026
Vertex Pharmaceuticals lobbying on a new issue.
New
['VET']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4689655
Financials: Quarterly capital spending jump became public on 17 Feb 2026
Vertex Pharmaceuticals spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.
This period
$149.4M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$68.7M
Typical spread (median absolute deviation)
$17.2M
How far from its usual level
+3.2
Same quarter last year
$92.6M
History used
6,119 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $68.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
21 Apr 2025confirmed
Confirmed across sources Lobbying and Short interest and volume
Vertex Pharmaceuticals(VRTX): had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 19 days.
Short interest and volume: Short interest spike, became public on 26 Mar 2025
Lobbying: Lobbying on a new issue, became public on 21 Apr 2025
The 14 Mar 2025 report against the 24 reports before it.
this reportearliernormal: 4.2MSee the evidence (2 changes)
Short interest and volume: Short interest spike became public on 26 Mar 2025
Vertex Pharmaceuticals had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year.
This period
5.8M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
4.2M
Typical spread (median absolute deviation)
224K
How far from its usual level
+3.7
Same report last year
4.1M
History used
2,632 days
the 14 Mar 2025 report24 earlier reportsnormal: 4.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Lobbying: Lobbying on a new issue became public on 21 Apr 2025
Vertex Pharmaceuticals lobbying on a new issue.
New
['DEF', 'TRD']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6139847
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 Feb 2022confirmed
Confirmed across sources Filings + Financials and Lobbying
Vertex Pharmaceuticals(VRTX): reported $630K of lobbying spend for the quarter ended 31 Dec 2021, 1.1× the same quarter last year, while it reported revenue of $2.1B for the quarter ended 31 Dec 2021, 1.3× the same quarter last year. Two unrelated kinds of activity within 21 days.
Lobbying: Lobbying spend jump, became public on 20 Jan 2022
Financials: Quarterly revenue change, became public on 15 Feb 2022
The quarter ended 31 Dec 2021 against the 8 quarters before it.
this quarterearliernormal: $435KSee the evidence (2 changes)
Lobbying: Lobbying spend jump became public on 20 Jan 2022
Vertex Pharmaceuticals reported $630K of lobbying spend for the quarter ended 31 Dec 2021, 1.1× the same quarter last year.
This period
$630K (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
$435K
Typical spread (median absolute deviation)
$35K
How far from its usual level
+3.8
Same quarter last year
$590K
History used
4,202 days
the quarter ended 31 Dec 20218 earlier quartersnormal: $435K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Financials: Quarterly revenue change became public on 15 Feb 2022
Vertex Pharmaceuticals reported revenue of $2.1B for the quarter ended 31 Dec 2021, 1.3× the same quarter last year.
This period
$2.1B (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
$1.6B
Typical spread (median absolute deviation)
$104.6M
How far from its usual level
+3.1
Same quarter last year
$1.6B
History used
4,658 days
the quarter ended 31 Dec 20218 earlier quartersnormal: $1.6B
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
lobbying on a new issue, while it spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 27 days.
See the evidence (2 changes)
Lobbying: Lobbying on a new issue became public on 21 Jan 2026
Vertex Pharmaceuticals lobbying on a new issue.
New
['VET']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4689655
Financials: Quarterly capital spending jump became public on 17 Feb 2026
Vertex Pharmaceuticals spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.
This period
$149.4M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$68.7M
Typical spread (median absolute deviation)
$17.2M
How far from its usual level
+3.2
Same quarter last year
$92.6M
History used
6,119 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $68.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
17 Feb 2026Financials change
spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.
Same quarter last year: $92.6M; its normal quarter is $68.7M.
See the evidence
This period
$149.4M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$68.7M
Typical spread (median absolute deviation)
$17.2M
How far from its usual level
+3.2
Same quarter last year
$92.6M
History used
6,119 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $68.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $145.7M on capital projects in the quarter ended 30 Jun 2025, 2.1× the same quarter last year.
Same quarter last year: $69.0M; its normal quarter is $63.6M.
See the evidence
This period
$145.7M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$63.6M
Typical spread (median absolute deviation)
$5.5M
How far from its usual level
+10.2
Same quarter last year
$69.0M
History used
3,378 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $63.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 19 days.
See the evidence (2 changes)
Short interest and volume: Short interest spike became public on 26 Mar 2025
Vertex Pharmaceuticals had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year.
This period
5.8M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
4.2M
Typical spread (median absolute deviation)
224K
How far from its usual level
+3.7
Same report last year
4.1M
History used
2,632 days
the 14 Mar 2025 report24 earlier reportsnormal: 4.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Lobbying: Lobbying on a new issue became public on 21 Apr 2025
Vertex Pharmaceuticals lobbying on a new issue.
New
['DEF', 'TRD']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6139847
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
21 Apr 2025Lobbying change
lobbying on a new issue.
See the evidence
New
['DEF', 'TRD']
Rule
only points whose every posting (and value revision) is at or before as_of
had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year.
Same report last year: 4.1M; its normal report is 4.2M.
See the evidence
This period
5.8M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
4.2M
Typical spread (median absolute deviation)
224K
How far from its usual level
+3.7
Same report last year
4.1M
History used
2,632 days
the 14 Mar 2025 report24 earlier reportsnormal: 4.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
drew 9,043 Wikipedia page views in the week of 27 Jan 2025, 2.8× the same week last year.
Same week last year: 3,280; its normal week is 1,520.
See the evidence
This period
9,043 (the week of 27 Jan 2025)
Normal week (median of 26 earlier)
1,520
Typical spread (median absolute deviation)
98.5
How far from its usual level
+37.6
Same week last year
3,280
History used
2,224 days
the week of 27 Jan 202526 earlier weeksnormal: 1,520
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6541714
28 Feb 2024Short interest and volume change
had 4.1M shares sold short in the 15 Feb 2024 report, 1.5× the same report last year.
Same report last year: 2.8M; its normal report is 2.9M.
See the evidence
This period
4.1M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
2.9M
Typical spread (median absolute deviation)
196K
How far from its usual level
+4.4
Same report last year
2.8M
History used
2,239 days
the 15 Feb 2024 report24 earlier reportsnormal: 2.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 90 entries; narrow the window or the kind of data to see older ones.
Not listed: 849 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
tiber creek group on behalf of vertex pharmaceuticals, vertex pharmaceuticals
Name
a10k_2025-exhibit211.htm, AIS Operating Co., Inc., a Delaware corporation (7), Alpine Immune Sciences Australia Pty Ltd, an Australian Company (7), Alpine Immune Sciences, Inc., a Delaware corporation and 46 more
Uei
Y4NLRU471XL7
Wikidata
Q2744099
Wikipedia
Vertex Pharmaceuticals
DOL H-1B labor condition applications and PERM certifications1475 data points1 Oct 2019 to 28 Sep 2026
Federal lobbying disclosures (LDA)24 records, 225 data points14 Feb 2008 to 30 Sep 2026
SEC Form 13F institutional holdings8 records, 481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)144 records11 Jan 2016 to 3 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1187 data points31 Dec 2007 to 31 Oct 2026
SEC Form 4 insider transactions733 records, 1532 data points4 Jan 2016 to 18 Nov 2026
FINRA short interest (twice monthly)627 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards9 data points6 May 2009 to 2 Feb 2010
Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026